#1 Clinical Trials Search in Europe

Ht-29-A

This article discusses the clinical trials of STC-1010, an innovative immunotherapy drug being tested for patients with advanced or metastatic colorectal cancer. The BreAK CRC trial aims to evaluate the safety, efficacy, and optimal dosing of STC-1010 when combined with standard-of-care treatments. This study offers hope for patients with limited treatment options and seeks to improve outcomes in colorectal cancer management.

Table of Contents

What is STC-1010?

STC-1010 is a new type of cancer treatment called immunotherapy that is being studied for patients with advanced colorectal cancer. It is also known as “Stimulated Tumor Cells-1010” [1]. STC-1010 is made up of specially prepared colorectal cancer cells that have been stimulated to potentially help the immune system fight cancer.

How does STC-1010 work?

STC-1010 contains six different types of colorectal cancer cells: HCT116-A, HCT116-B, HT-29-A, HT-29-B, LOVO-A, and LOVO-B [1]. These cells have been specially prepared in a laboratory to potentially stimulate the patient’s immune system to recognize and attack similar cancer cells in the body. This approach aims to harness the power of the immune system to fight cancer.

Who is STC-1010 for?

STC-1010 is being studied for patients with unresectable locally advanced or metastatic colorectal cancer [1]. This means:

  • The cancer has spread to nearby tissues or lymph nodes and cannot be completely removed by surgery (locally advanced)
  • Or, the cancer has spread to distant parts of the body (metastatic)
  • And the cancer cannot be cured by surgery alone

Clinical Trial Details

STC-1010 is currently being tested in a clinical trial called the BreAK CRC trial [1]. This trial has two main parts:

  1. Phase I: This part aims to determine the safety of STC-1010 and find the right dose to use.
  2. Phase IIA: This part will study how well STC-1010 works in treating colorectal cancer.

The trial is testing STC-1010 in combination with other cancer treatments, including:

  • mFOLFOX6: A combination of chemotherapy drugs
  • Bevacizumab: A targeted therapy that helps stop the growth of blood vessels that feed tumors

Potential Benefits

While it’s important to note that STC-1010 is still experimental, researchers hope it may offer several potential benefits:

  • A new treatment option for patients with advanced colorectal cancer
  • Possible improved effectiveness when combined with standard treatments
  • Potential to harness the body’s own immune system to fight cancer

Safety Considerations

As with any new treatment, safety is a top priority. The clinical trial is carefully designed to monitor for side effects and determine the safest way to use STC-1010. Some important points to note:

  • STC-1010 is given by intradermal injection, which means it’s injected just under the skin [1].
  • Patients in the trial will be closely monitored for any side effects or reactions.
  • The trial has specific criteria for who can participate to ensure patient safety.

It’s important to remember that STC-1010 is still being studied, and more research is needed to fully understand its effectiveness and safety. If you have colorectal cancer and are interested in learning more about this trial, talk to your oncologist about whether it might be an option for you.

Aspect Details
Trial Name BreAK CRC (001) trial
Drug Tested STC-1010 (immunotherapy)
Condition Unresectable locally advanced or metastatic colorectal cancer
Trial Phases Phase I/IIA
Primary Objectives Phase I: Safety profile and optimal dose determination
Phase IIA: Clinical efficacy assessment
Treatment Regimen STC-1010 + Standard of Care (mFOLFOX6 + bevacizumab)
Key Eligibility Adults 18-75, specific tumor characteristics, adequate organ function
Primary Endpoint Phase IIA: Progression-free survival rate at 12 months

FAQ

  • What is STC-1010 and how does it work? STC-1010 is an immunotherapy drug being tested for advanced colorectal cancer. It works by stimulating the body's immune system to fight cancer cells. The drug is administered along with standard chemotherapy and other treatments to potentially enhance their effectiveness.
  • Who is eligible for the BreAK CRC trial? The trial is primarily for adults aged 18-75 with unresectable locally advanced or metastatic colorectal cancer. Participants must meet specific health criteria, including adequate organ function and performance status. The study includes both patients who haven't received prior treatment and those who have progressed after immunotherapy.
  • What are the main objectives of the trial? The trial has two phases. Phase I aims to assess the safety of STC-1010 and determine the optimal dose. Phase IIA focuses on evaluating the clinical effectiveness of STC-1010 when combined with standard treatments for colorectal cancer.
  • How is the treatment administered in the trial? Participants receive STC-1010 along with standard chemotherapy (mFOLFOX6) and bevacizumab. The treatment is given in cycles, with an initial induction phase followed by a maintenance phase. The exact dosing and schedule are determined during the trial.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a new treatment that may be more effective than standard options. However, as with any clinical trial, there are risks of side effects and the possibility that the treatment may not be effective. The trial closely monitors participants for any adverse events and adjusts treatment as necessary.

Ongoing Clinical Trials on Ht-29-A

  • Study on STC-1010 and Drug Combination for Patients with Advanced or Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Unresectable: A tumor that cannot be completely removed through surgery due to its size, location, or spread.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Standard of Care (SOC): The currently accepted and widely used treatment for a specific condition.
  • mFOLFOX6: A chemotherapy regimen commonly used to treat colorectal cancer, consisting of multiple drugs.
  • Bevacizumab: A targeted therapy drug that works by blocking the growth of blood vessels that feed tumors.
  • MSS/pMMR: Microsatellite Stable/proficient Mismatch Repair, referring to specific genetic characteristics of the tumor.
  • MSI-H/dMMR: Microsatellite Instability-High/deficient Mismatch Repair, another set of genetic tumor characteristics.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Dose-Limiting Toxicity: Side effects severe enough to prevent an increase in the dose of a drug being tested.
  • ECOG Performance Status: A scale used to assess how a patient's disease affects their daily living abilities and determine appropriate treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-stc-1010-and-drug-combination-for-patients-with-advanced-or-metastatic-colorectal-cancer/